Literature DB >> 30957461

L-arginine pathway metabolites can discriminate paroxysmal from permanent atrial fibrillation in acute ischemic stroke.

Péter Csecsei1, Réka Várnai, Lajos Nagy2, Sándor Kéki3, Tihamér Molnár4, Zsolt Illés1,5,6, Nelli Farkas7, László Szapáry1.   

Abstract

BACKGROUND AND
PURPOSE: Atrial fibrillation (AF) is the most common arrhythmia diagnosed in clinical practice. We aimed to measure the L-arginine pathway metabolites as well as their ratios in patients with different types of AF or sinus rhythm and to explore the relationship among the markers and clinical variables in the subacute phase of acute ischemic stroke (AIS).
METHODS: A total of 46 patients with AIS were prospectively enrolled. The patients were divided into three groups based on diagnosis of either sinus rhythm, paroxysmal or permanent AF. Plasma concentration of the L-arginine pathway metabolites were analyzed at post-stroke 24 hours in the three rhythm groups. Besides, clinical variables and laboratory data were recorded.
RESULTS: Asymmetric dimetylarginine (ADMA) was significantly higher in patients with permanent AF compared to sinus rhythm (p<0.001). Both ADMA (p<0.001) and symmetric dimethylarginine (SDMA) (p<0.002) at 24 hours were significantly higher among patients with permanent AF compared to those with paroxysmal AF. The L-arginine/SDMA (p<0.031) ratios at 24 hours were significantly higher among patients with sinus rhythm compared to those with permanent AF. ROC analysis also revealed that plasma SDMA cut-off level over 0.639 μmol/L discriminated permanent AF from paroxysmal AF or sinus rhythm with a 90.9% sensitivity and 77.1% specificity. Neutrophil-lymphocyte ratio also showed significantly higher value in individuals with both paroxysmal and permanent AF (p=0.029).
CONCLUSION: Plasma level of SDMA could discriminate permanent from paroxysmal AF in the subacute phase of ischemic stroke. In addition, an increased neutrophil-lymphocyte ratio may suggest inflammatory process in the evolution of atrial fibrillation.

Entities:  

Keywords:  L-arginine; atrial fibrillation; ischemic stroke

Mesh:

Substances:

Year:  2019        PMID: 30957461     DOI: 10.18071/isz.72.0079

Source DB:  PubMed          Journal:  Ideggyogy Sz        ISSN: 0019-1442            Impact factor:   0.427


  5 in total

1.  An Integrated Metabolomic Screening Platform Discovers the Potential Biomarkers of Ischemic Stroke and Reveals the Protective Effect and Mechanism of Folic Acid.

Authors:  Yan-Hui Yang; Lei Lei; Yin-Ping Bao; Lu Zhang
Journal:  Front Mol Biosci       Date:  2022-05-18

2.  The Impact of Diabetes Mellitus and Admission Hyperglycemia on Clinical Outcomes after Recanalization Therapies for Acute Ischemic Stroke: STAY ALIVE National Prospective Registry.

Authors:  Peter Janos Kalmar; Gabor Tarkanyi; Zsofia Nozomi Karadi; Laszlo Szapary; Edit Bosnyak
Journal:  Life (Basel)       Date:  2022-04-25

3.  Evaluating Serum Heat Shock Protein Levels as Novel Biomarkers for Atrial Fibrillation.

Authors:  Denise M S van Marion; Eva A H Lanters; Kennedy S Ramos; Jin Li; Marit Wiersma; Luciënne Baks-Te Bulte; Agnes J Q M Muskens; Eric Boersma; Natasja M S de Groot; Bianca J J M Brundel
Journal:  Cells       Date:  2020-09-16       Impact factor: 6.600

4.  Optimization of Large Vessel Occlusion Detection in Acute Ischemic Stroke Using Machine Learning Methods.

Authors:  Gabor Tarkanyi; Akos Tenyi; Roland Hollos; Peter Janos Kalmar; Laszlo Szapary
Journal:  Life (Basel)       Date:  2022-02-03

5.  L-arginine, asymmetric and symmetric dimethylarginine for early outcome prediction in unselected cardiac arrest victims: a prospective cohort study.

Authors:  Beata Csiszar; Zsolt Marton; Janos Riba; Peter Csecsei; Lajos Nagy; Kalman Toth; Robert Halmosi; Barbara Sandor; Peter Kenyeres; Tihamer Molnar
Journal:  Intern Emerg Med       Date:  2021-06-03       Impact factor: 3.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.